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In patients with impaired liver function and hepatic encephalopathy (HE), consistent
elevations of blood ammonia concentration suggest a crucial role in the pathogenesis
of HE. Ammonia and acetate are metabolized in brain both primarily in astrocytes. Here,
we used dynamic [11C]acetate PET of the brain to measure the contribution of astrocytes
to the previously observed reduction of brain oxidative metabolism in patients with liver
cirrhosis and HE, compared to patients with cirrhosis without HE, and to healthy subjects.
We used a new kinetic model to estimate uptake from blood to astrocytes and astrocyte
metabolism of [11C]acetate. No significant differences of the rate constant of oxidation
of [11C]acetate (k3) were found among the three groups of subjects. The net metabolic
clearance of [11C]acetate from blood was lower in the group of patients with cirrhosis and
HE than in the group of healthy subjects (P < 0.05), which we interpret to be an effect of
reduced cerebral blood flow rather than a reflection of low [11C]acetate metabolism. We
conclude that the characteristic decline of whole-brain oxidative metabolism in patients
with cirrhosis with HE is not due to malfunction of oxidative metabolism in astrocytes.
Thus, the observed decline of brain oxidative metabolism implicates changes of neurons
and their energy turnover in patients with HE.
Keywords: astrocytes, brain energy metabolism, kinetic modeling, mitochondria, positron emission tomography
INTRODUCTION
Hepatic encephalopathy (HE) is a common and recurrent com-
plication of liver cirrhosis. Increased blood ammonia is held to
be a key pathogenic factor (Ott and Vilstrup, 2014). Compared to
patients with cirrhosis without HE and healthy subjects, patients
with cirrhosis andHE type C had low cerebral oxygenmetabolism
(CMRO2) and cerebral blood flow (CBF) in inverse proportion to
arterial blood ammonia concentration (Iversen et al., 2009; Dam
et al., 2013). Both variables rise to normal after recovery from HE
(Dam et al., 2013), indicating that low values of CMRO2 and CBF
during HE are related to the encephalopathy rather than to the
cirrhosis. Oxygen delivery to the brain by the circulation did not
limit the magnitude of CMRO2, suggesting that the reduction of
CBF is secondary to the reduction of CMRO2 (Iversen et al., 2009;
Gjedde et al., 2010). In brain, ammonia reacts with glutamate
dehydrogenase and glutamine synthetase to form glutamate and
glutamine, respectively, the former of which is linked to oxida-
tive metabolism. The disposal of ammonia in the brain takes place
mainly via formation of glutamine by glutamine synthetase which
is located exclusively in astrocytes. This is the basis for the present
hypothesis that the reduction in CMRO2 during cirrhosis with
HE reflects reduced oxidative metabolism in astrocytes.
Acetate is converted to acetyl-CoA and undergoes subsequent
oxidative metabolism in the TCA cycle of most cells. However,
in the brain, acetate is metabolized in the astrocytes because the
monocarboxylate transporter 2 (MCT2), the only MCT of neu-
rons, fails to recognize acetate to the same extent as MCT1 located
in endothelial cells and astrocytes (Waniewski and Martin, 1998;
Patel et al., 2010). Therefore, measurement of acetate metabolism
commonly is used to assess the oxidative metabolism of astrocytes
(Patel et al., 2010). In the present study, we used positron emis-
sion tomography (PET) with tracer [1-11C]acetate ([11C]acetate)
to assess the oxidative metabolism of astrocytes in patients with
cirrhosis, with or without HE, as well as in healthy subjects.
Each subject had PET with [11C]acetate immediately after the
measurements of CMRO2 and CBF, published separately (Iversen
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et al., 2009). A model of cerebral acetate kinetics was developed
for the present report. Based on the findings of reduced CMRO2
in patients with cirrhosis and HE (Iversen et al., 2009) and the
restriction of the ammonia and acetate metabolism to astrocytes,
we tested the hypothesis that [11C]acetate metabolism is reduced
in the patients with HE, as a measure of oxidative metabolism
by astrocytes. Failure to uphold the hypothesis would mean that
effects of ammonia in astrocytes do not explain the reduced
oxidative metabolism measured in HE.
MATERIALS AND METHODS
SUBJECTS
According to the design of the study, each of 21 subjects, seven
in each of the groups of patients with cirrhosis and HE type
C, patients with cirrhosis without HE, and healthy subjects, was
scheduled to have an [11C]acetate PET study after the completion
of measurements of CMRO2 and CBF (Iversen et al., 2009; Gjedde
et al., 2010). However, only six patients with HE completed the
[11C]acetate study. In three other subjects admitted to the study,
the design could not be fulfilled because of technical failure of one
of the three successive PETmeasurements. The [11C]acetate mea-
surements could be completed in only five of the seven healthy
subjects. In the group of patients with cirrhosis, one of the seven
patients was unable to inhale [15O]oxygen and was excluded from
the previous presentation of the oxygen and blood flow data.
Thus, six patients with HE, seven patients with cirrhosis without
FIGURE 1 | Kinetic model of [11C]acetate metabolism in human brain.
[11C]Acetate enters the astrocytes from blood through either
carrier-mediated transport (MCT1) or passive diffusion, characterized by the
unidirectional clearance K1, [11C]Acetate in the astrocytes either return to
blood, characterized by the rate constant k2, or is converted to
[11C]acetyl-CoA, thereby entering the tricarboxylic acid (TCA) cycle, where it
is joined into amino acids produced from oxaloacetate and α-ketoglutarate,
irreversible processes characterized by the rate constant k3, before it is
converted to [11C]CO2, which leaves the cell by passive diffusion into the
blood, characterized by the rate constant k5.
Table 1 | Patient Characteristics (revised from Iversen et al., 2009).
Cirrhosis with HE (n = 6) Cirrhosis without HE (n = 7) Healthy subjects (n = 5)
Female/Male 1/5 1/6 1/4
Age (years) 58 (48–62) 54 (45–63) 54 (46–65)
Body weight (kg) 75 (45–103) 86 (62–107) 83 (69–89)
MAP (mmHg) 87*(81–92) 90*(73–107) 106 (102–112)
HEPATIC ENCEPHALOPATHY
Arterial ammonia (μmol/l) 129 ± 64* 76 ± 25* 21 ± 6
New haven coma grade I:3; II:1; III:2 None None
Glasgow coma score 10:1; 12:2; 14:1; 15:2 15:7 15:5
Continuous reaction time (Index) 0.79 (0.33–1.93)*,** 2.05 (0.98–3.02) 2.38 (2.14–2.76)
ARTERIAL BLOOD GASES
pH 7.49 ± 0.02*,** 7.46 ± 0.03 7.43 ± 0.03
pO2 (kPa) 11.1 ± 1.3 10.0 ± 0.9 11.2 ± 0.9
O2 Saturation (%) 97.1± 1.0 95.8 ± 1.4 97.3 ± 1.5
pCO2 (kPa) 4.3 ± 0.7* 4.9 ± 0.4 5.4 ± 0.4
SBC (mmol/l) 26.2 ± 2.7 27.0 ± 2.1 26.4 ± 1.6
METABOLIC MARKERS
Plasma glucose (mmol/l) 6.3 ± 1.9 6.2 ± 1.7 5.3 ± 0.4
Plasma ketone bodies (mmol/l) 0.2 ± 0.1 0.3 ± 0.1 0.3 ± 0.3
LIVER TESTS
Child-Pugh class A:0; B:1; C:5 A:2; B:4; C:1 None
GEC: Pt/Ref† 0.51 (0.40–0.61) 0.56 (0.45–0.68) 1.00 (0.85–1.15)
HE, hepatic encephalopathy; n, number of subjects; MAP, mean arterial pressure.
†GEC, galactose elimination capacity is shown as patient GEC relative to GEC for a healthy subject of same age and body weight.
Values are given as median (range) or mean ± SD.
*Mean value is significantly different from mean of healthy subjects (P < 0.05).
**Mean value is significantly different from mean of cirrhosis without HE (P < 0.05).
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HE, and five healthy subjects completed the [11C]acetate studies.
Clinical and laboratory characteristics therefore differ in minor
respects from those given in the oxygen consumption and blood
flow paper (Iversen et al., 2009; Gjedde et al., 2010) (Table 1). At
the time of the study, the patients received no specific treatment
for HE.
ETHICS
The study was performed in accordance with the Helsinki II
Declaration and approved by the Ethics Committee of Aarhus
County. We obtained informed consent from each participant.
The radiation dose averaged 2.45 mSv ([11C]acetate).
TRACER PRODUCTION
[11C]Carbon dioxide was produced in the Aarhus PET Center’s
16.8 MeV PETtrace cyclotron (GE Medical Systems, Uppsala,
Sweden) and a slight modified procedure of Roeda et al. (2002)
was applied to convert [11C]carbon dioxide to [11C]acetate.
Briefly, we trapped 11CO2 in a 10-ml vial containing methylmag-
nesium chloride (1ml, approximately 100mmol/l). After com-
plete trapping, we added sterile acetic acid (9ml, 1mmol/l) to
quench the Grignard solution.We purified the product by passing
it over H+ and Ag+ cartridges and then trapped the [11C]acetate
on an OH cartridge. We washed the product twice with 10ml of
sterile water. Finally, we used 10ml of sterile citrate buffer (pH
4.7) to elute the [11C]acetate from the OH cartridge through a
0.22μm filter into a sterile product vial. We measured the activ-
ity of the final product and used a sterile needle and syringe
to withdraw approximately 0.3ml of the formulation for qual-
ity control. Typical synthesis time was 7min (±2min) with a
yield of 6 GBq (±2 GBq) after EOS with 10min bombardment
with 40μA.
PET RECORDINGS
The subjects were told not to take drugs or food for 8 h before
the studies but were free to drink water. Catheters were placed
Table 2 | Parameters of brain [11C]acetate metabolism.
Cirrhosis with HE (n = 6) Cirrhosis without HE (n = 7) Healthy subjects (n = 5)
K1(ml blood (cm−3 brain tissue) min−1) WB 0.24±0.043 0.41±0.040* 0.43±0.047*
GM 0.23±0.046 0.41±0.043* 0.41±0.051*
WM 0.19±0.026 0.27±0.024** 0.23±0.028
k2(min−1) WB 0.58±0.061 0.93±0.057* 0.90±0.068*
GM 0.58±0.067 0.95±0.062* 0.90±0.074*
WM 0.47±0.049 0.61±0.046** 0.48±0.054
k3(min−1) WB 0.098±0.014 0.094±0.013 0.11±0.015
GM 0.096±0.014 0.097±0.013 0.11±0.016
WM 0.130±0.046 0.072±0.041 0.12±0.050
k5(min−1) WB 0.087±0.012 0.11±0.012 0.13±0.014*
GM 0.075±0.011 0.11±0.010* 0.12±0.013*
WM 0.135±0.031 0.18±0.031 0.17±0.035
V0(ml blood (cm−3 brain tissue)) WB 0.021±0.014 0.039±0.0129 0.042±0.0153
GM 0.022±0.014 0.037±0.0138 0.042±0.0163
WM 0.009±0.008 0.019±0.0076 0.013±0.0090
K (ml blood (cm−3 brain tissue) min−1) WB 0.034±0.008 0.038±0.0310 0.047±0.0069**
GM 0.033±0.008 0.038±0.0330 0.045±0.0060**
WM 0.041±0.013 0.028±0.0240 0.046±0.0180
Oxidative index (k3/k5) WB 1.13±0.23 0.83±0.14 0.84±0.15
GM 1.27±0.27 0.90±0.15 0.96±0.17
WM 0.96±0.40 0.41±0.24 0.72±0.33
K1 ([15O]water) (ml blood cm−3 brain tissue min−1)† WB 0.24±0.030 0.41±0.061* 0.43±0.041*
GM 0.26±0.033 0.45±0.072* 0.48±0.050*
WM 0.21±0.030 0.31±0.044* 0.28±0.011*
HE, hepatic encephalopathy; n, number of subjects; K1, unidirectional clearance of [11C]acetate transfer from blood to astrocytes; k2, rate constant of [11C]acetate
by return to blood from astrocytes; k3,rate constant of [11C]acetate by conversion to [11C]acetylCoA, thereby entering the tricarboxylic acid cycle (TCA); k5, passive
diffusion of 11CO2 into the blood; V0, Apparent distribution volume in vascular space; K, net metabolic clearance of [11C]acetate; WB, whole brain region excl.
ventricles; GM, gray matter region; WM, white matter region.
Values are given as mean ± SD.
*Mean value is significantly different from mean of the group of patients with cirrhosis and HE (P < 0.01).
**Mean value is significantly different from mean of the group of patients with cirrhosis and HE (P < 0.05).
†Revised from Iversen et al. (2009).
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percutaneously in a radial artery for blood sampling and in a
cubital vein for intravenous injections of the tracers. The sub-
jects were placed in the supine position with their head within
the 15 cm field-of-view of the tomograph (ECAT EXACT HR 47,
CTI, Knoxville, TN), equipped with a neck shield as previously
described (Iversen et al., 2009).
In each subject, the PET recording with [11C]acetate took
place after completion of the measurements of CMRO2 and
CBF (Iversen et al., 2009). A median dose of 459 MBq (range
128–580 MBq) [11C]acetate were given as intravenous injec-
tion during the initial 20 s of a dynamic PET recording of the
brain using a protocol that comprised 50 frames of 18 × 5 s,
12 × 10 s, 7 × 30 s, 1 × 120 s, and 12 × 180 s for a total of 45min.
Attenuation correction, radioactivity decay correction and recon-
struction procedures were as described previously (Iversen et al.,
2009).
BLOOD SAMPLES
During the [11C]acetate PET recordings, we manually collected
0.5ml arterial blood samples at the following intervals: 18 every
5th s, 9 every 10th s, 12 every 60th s, and every 5th min for a
total of 45min. Blood [11C] radioactivity concentrations were
measured in a well counter (Packard Instruments Co., Meriden,
CT, USA), cross-calibrated with the tomograph and corrected for
radioactive decay to the start of the scanning. Arterial plasma
concentration of ammonia (van Anken and Schiphorst, 1974)
was significantly higher in the patients than in healthy subjects
and tended to be higher in the patients with HE than in the
patients without HE, although this difference was not significant
(Table 1).
MAGNETIC RESONANCE IMAGING
T1-weighted magnetic resonance imaging (MRI) was performed
in each subject for definition of specific brain regions for the PET
measurements by co-registration as previously described (Iversen
et al., 2009).
TRACER KINETIC ANALYSIS
The kinetic analysis of [11C]acetate uptake from blood and
metabolism in astrocytes is complicated by rapid metabolism of
[11C]acetate to [11C]CO2. This requires a model that includes
three successive steps: transport of [11C]acetate from blood to
brain cells (K1; ml blood (cm−3 brain tissue) min−1), back-
flux from cells to blood (rate constant k2; min−1), metabolism
of [11C]acetate to [11C]acetyl-CoA and [11C]CO2 (k3; min−1),
flux of [11C]CO2 out of the brain to the blood circulation (k5;
min−1) and specifically into the apparent distribution volume in
the vascular space (V0; ml blood (cm−3 brain tissue)) (Figure 1).
We symbolize the volume of distribution of labeled molecules
remaining in the vascular bed of the brain by the term V0,
assumed to include effects of labeled tracer metabolites such as
[11C]CO2, as described below. As the [11C]acetate conversion to
[11C]CO2 is irreversible, the model has no rate constant for the
conversion of 11C-labeled metabolites to the [11C]acetate itself.
The constant k3 is a measure of the rate constant for the oxida-
tive metabolism of blood-borne [11C]acetate in the astrocytes.
We note that this may be different from the net whole-brain
metabolic clearance of acetate.
We used a statistical non-linear mixed effects model to esti-
mate the parameters of the kinetic model K1k2k3k5V0 (Williams
and Ette, 2000) described by the following equations:
FIGURE 2 | [11C]acetate PET images. Summed average [11C]-PET images from time of injection of [11C]acetate to 45min in the groups of patients with
cirrhosis and HE (HE), patients with cirrhosis without HE (CL) and healthy subjects (HC), n, number of subjects. Data are presented on a logarithmic scale.
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m1 = Vo c1
m2 = K1
∫ T
0
c1 e
−(k2+k3)(T−t) dt
m3 = K1k3
∫ u
0
[∫ T
0
c1 e
−(k2+k3)(T−t) dt
]
e−k5(u−T) dt
where m1, m2, and m3 are the tracer quantities in compart-
ments 1–3 (Figure 1); c1(t) is the arterial tracer concentration
of compartment 1 as function of time t after onset of record-
ing; and u and T are dummy time variables. This approach avoids
“overfitting” to themeasured data in individual subjects by simul-
taneously fitting the model to all subjects, admitting different
kinetic parameters in each of the three groups of subjects but
allowing only modest deviations within each group. The latter
was ensured by modeling subjects as random effects. In con-
trast, a two-step procedure with individual model fitting followed
by parameter averaging and group testing may lead to “overfit-
ting” and variance inflation in the first step and in the second
step. The procedure overcomes a potentially poor match between
the group-models with averaged kinetic coefficients compared to
individual time activity curves that may occur when the aver-
aging step is performed irrespectively and independently of the
measured data.
The kinetic model was fitted to the PET data fromwhole-brain
and each of nine predefined brain regions of each subject (cere-
bellum, frontal, parietal, temporal and occipital lobes, striatum,
thalamus, total gray matter, and total white matter), see Results.
We obtained estimates of rate constants and clearances defined by
the model, including the net metabolic clearance of [11C]acetate
K as K1k3/(k2 + k3) (Gjedde, 1982) listed in Table 2. We also esti-
mated the k3/k5 ratio as an oxidative index, expressing the relative
rates of oxidative metabolism in astrocytes and flow-dependent
removal of [11C]-metabolites from brain tissue to blood.
We did not make any specific correction for the appear-
ance of [11C]CO2 in blood. The question of the accumula-
tion of [11C]CO2 in blood, produced from the metabolism of
[11C]acetate, has been dealt with on a number of occasions (e.g.,
Shields et al., 1992). In the accompanying editorial, Gjedde (1992)
stated that “[if] the distribution of [11C]CO2 initially follows
blood flow, reflecting rapid transfer into the tissue, it may be suf-
ficient simply to calculate tissue curves that assume instant steady
state with the blood, at half the blood level.” After administration
of [11C]acetate, Shields et al. found that [11C]-labeled carbon
dioxide, 1–2min after injection of [11C]acetate, represented a
constant proportion of about 60% of the [11C]-activity in blood,
and that brain tissue [11C]-activity followed blood [11C]-activity
at approximately the same level. This means that the carbon
dioxide activities in blood and brain tissue kinetically can be
attributed to part of the vascular background. In the present
analysis, the vascular background volume V0 was included specif-
ically for this reason. We tested this assertion by confirming the
absent relation of the estimates of V0 to the estimates of the flow-
sensitive parameters K1, k2, and k5, and the V0 estimates’ poor
relation to the estimates of k3, which is an indicator of the capacity
for metabolism of [11C]acetate in brain tissue.
FIGURE 3 | Individual parameter estimates. Patients with cirrhosis
and hepatic encephalopathy (HE) ( ), patients with cirrhosis without
HE ( ), and healthy subjects ( ). (A) Rate constant of whole brain
astrocyte oxidative metabolism, k3vs. unidirectional clearance from
blood-to-brain tissue of [11C]acetate, K1. (B) Rate constant for return
of [11C]acetate from the astrocytes to blood, k2 vs. K1. (C) Passive
diffusion of [11C]CO2 from the astrocytes into the blood, k5 vs. K1.
(D) Apparent distribution volume in vascular space, V0 vs. K1. Solid
line indicates a tendency.
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STATISTICS
We observed no significant left-right differences for any of the
present kinetic parameter estimates in any of the predefined
regions, and we therefore report the estimates of the kinetic
parameters as averages for right and left brain regions. We used a
Two-Way ANOVA test to compare the oxidative indices between
groups, with probability values of less than 0.05 as the threshold
of statistical significance. We also determined the significance of
relations among selected individually estimated rate constants for
whole-brain, using linear regression with probability values of less
than 0.05 as the threshold of statistical significance.
RESULTS
The rate constant of oxidation of [11C]acetate, k3, used here to
represent the efficiency of oxidative metabolism of [11C]acetate
in astrocytes, did not reveal any significant differences among
the three groups of subjects, in any of the brain regions studied
(Table 2).
Figure 2 illustrates the observation that the average summed
[11C]-activity was lower in the group of patients with cirrhosis
and HE compared to the group of patients with cirrhosis without
HE and that of healthy subjects. These differences were not sig-
nificantly related to differences of k3 among the three groups of
subjects, for any brain region.
The group of patients with cirrhosis and HE had lower
whole-brain and gray-matter unidirectional clearances K1 of
[11C]acetate from blood to brain tissue than the groups of
patients without HE and healthy subjects (both P < 0.01). There
were no significant differences of K1 between the patients with-
out HE and the healthy subjects. The highest values of K1
were seen in cerebellum, occipital and parietal cortices, and the
lowest values in striatum, thalamus, and frontal and temporal
cortices.
Whole-brain individual estimates of K1 and k3 of [11C]acetate
were not significantly correlated (Figure 3A). In contrast,
whole-brain individual estimates of K1 were significantly corre-
lated to k2 and k5 (both P < 0.0001), but not to V0 (P = 0.82) as
shown in (Figures 3B–D).
The group of patients with cirrhosis and HE had significantly
lower whole-brain and gray-matter metabolic clearances K of
[11C]acetate than healthy subjects (Table 2). White matter had
significantly lower values of K in all three groups of subjects com-
pared to whole-brain and gray matter regions (Table 2), but the
decline was less pronounced in the group of cirrhosis patients
with HE.
DISCUSSION
In this study we fitted a novel model of [11C]acetate
metabolism in brain tissue to brain [11C]acetate PET recordings.
Figure 4 presents the time courses of the whole-brain [11C]-
concentrations observed and those predicted by three different
models for each of the three groups of subjects. The mod-
els include a simple flow model (K1, k2, V0), an irreversible
metabolism model (K1, k2, k3, V0), and the current model
with metabolite efflux (K1, k2, k3, k5, V0). The different time
courses illustrate the discrimination among the predictions of
the three formulations of the model, i.e., with the rate constants
set to zero or not. We note that the present model fitted the
data best.
The rate constant of oxidation of [11C]acetate in astrocytes (k3
of [11C]acetate) was not significantly different between the three
groups of subjects (Table 2) and the net clearance of [11C]acetate
(K) was not related to the arterial blood ammonia concentra-
tion or to the rate of oxygen consumption (Figures 5A,B). A
possible explanation could be relatively lower aerobic glycolysis
during HE, in which the consumption of glucose is replaced by
acetate, with lower generation of lactate at normal brain tissue
oxygen tensions (Gjedde et al., 2010). Lower generation of lactate
in oligodendrocytes, lower blood flow, and up-regulation of the
MCT1 transporters have been seen in other conditions, such as
FIGURE 4 | Predicted time-activity curves for three whole-brain model
configurations. (A) Average data sets for patients with cirrhosis and hepatic
encephalopathy (HE). (B) Patients with cirrhosis without HE. (C) Healthy
subjects. Each panel shows the observed values, the fitted values using a
K1k2k3k5V0 model (“full” model), and the predicted behaviors of the
K1k2k3V0 and K1k2V0 models. K1, unidirectional clearance from blood-to-brain
tissue of [11C]acetate. k2, rate constant for return of [11C]acetate from the
astrocytes to blood. k3, rate constant of whole brain astrocyte oxidative
metabolism. k5, passive diffusion of [11C]O2 from the astrocytes into the
blood. V0, apparent distribution volume in vascular compartment.
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FIGURE 5 | Net metabolic clearance and unidirectional clearance from
blood-to-brain tissue of [11C]acetate vs. arterial blood ammonia,
unidirectional clearance of H2[15O] and cerebral metabolic rate of
oxygen. Patients with cirrhosis and hepatic encephalopathy (HE) ( ),
patients with cirrhosis without HE ( ), and healthy subjects ( ). (A) Net
metabolic clearance of [11C]acetate, K vs. arterial blood ammonia
concentration (the latter from Iversen et al., 2009). (B) Net metabolic
clearance of [11C]acetate, K vs. cerebral metabolic rate of oxygen, CMRO2
(the latter from Iversen et al., 2009). (C) Unidirectional clearance from
blood-to-brain tissue of [11C]acetate, K1 vs. that K1 of H2[15O] (the latter
from Iversen et al., 2009); the straight line shows line of identity. Solid line
indicates a tendency.
induced ischemia and epilepsy (Tseng et al., 2003; Rinholm et al.,
2011).
The close correlation between K1of [11C]acetate and CBF (cal-
culated as K1 of H152 O/0.85) (Iversen et al., 2009) as seen in
Figure 5C, suggests that [11C]acetate uptake from blood is flow-
determined by virtue of the great capacity of acetate transport
by MCT1 across the blood-brain barrier and from the intersti-
tial space into the astrocytes. The position of the observations
just below the line of identity indicates an extraction fraction
of [11C]acetate that is not much lower than that of [15O]water.
This indicates that estimates of the K1 of [11C]acetate might
be used as indices of CBF. Significant correlations of the esti-
mates of K1 to k2 (P = 0.0001) and k5 (P = 0.0001), respec-
tively (Figures 3B,C), can be explained by flow-dependence of
K1, k2, and k5.
The higher k3/k5 ratio in patients with HE than in the
two other group of subjects (Table 2) suggests that the oxida-
tive metabolism of the astrocytes declines less than the rates
of metabolite washout by the blood flow in patients with HE
compared to subjects without HE.
Figure 2 shows all species of radioactivity within each of the
three groups of subjects. The kinetic model deciphers the separate
populations of labeled molecules, and their dynamic relation-
ships, shown here to reveal similar fractions of the acetate pools
being converted to substrates of the TCA cycles of the three
groups. Of course, if significant differences of pharmacologically
active pools of acetate existed, they would be reflected in differ-
ent metabolic fluxes of acetate, but here we deal exclusively with
tracer amounts of acetate, used solely to determine the enzyme
activity of conversion to Acetyl-CoA in the three groups. There is
practically no unlabeled acetate present. Of course, when ammo-
nia concentrations differ, their metabolic fluxes would differ in
proportion to the concentration differences.
The model used in this study is more complex than previously
publishedmodels ofWyss et al. (2009), Lanz et al. (2012), empha-
sizing the observation that the previous models had only two
parameters (K1 and k2) compared to the current model with five
parameters (K1, k2, k3, k5, and V0). Wyss et al. (2009) interpret
the clearance of activity (k2 in their model) as loss of [11C]CO2
generated by glial oxidation, and they found this not to be affected
by increased CBF in their rat model. It is unclear how the (Wyss
et al., 2009) model would account for the clearance of acetate as
independent from the clearance of CO2. In the present model, K1,
k2, and k5 all depend strongly on the rate of blood flow, K1 as a
clearance, k2 and k5 as fractional clearances.
Astrocytic oxidative metabolism is generally held to be of the
order of 20% only of the total brain oxidative metabolism (Hyder
et al., 2010). In the present study. the blood flow reduction is
likely to be the consequence rather than the cause of low oxygen
metabolic rate is compromised, as previously reported (Gjedde
et al., 2010).
The passive diffusion of monocarboxylic acids is known to be
considerably lower than the facilitated diffusion across endothe-
lial and other cell membranes (Cremer et al., 1979). Indeed,
the actual uptake into neurons is much less than into astrocytes
because of deficient facilitated rather than passive diffusion in the
present study. In addition, the k3 magnitudes were shown not
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to differ, regardless of how large a proportion of the activity of
the acetyl-CoA synthetase, estimated in the present study, actually
reflected action in neurons.
In the HE condition, brain content of glutamine is
likely to be elevated and could a potential confounder in
the current study. The so-called “trojan horse” hypothesis
claims that the enlarged glutamine pool is destructive to
astrocytes, which would tend to be at variance with cur-
rent evidence (Brusilow et al., 2010) and that the rate of
oxidation of labeled acetate (k3) is unchanged in the present
study.
As far as we know, the current study is the first to test and
model a pathological state using [11C]acetate PET in humans,
except for the one PET study with [11C]acetate of acute alco-
hol intoxication by Volkow et al. (2013), which did not report
a detailed kinetic model. In previous studies, we demonstrated
that ammonia has no inhibitory effect on the tricarboxylic acid
cycle activity in cultured astrocytes (Johansen et al., 2007; Bak
et al., 2009). In the same studies TCA cycle of cultured neu-
rons (mainly glutamatergic) were not inhibited by ammonia
as well. Thus, reduction of neuronal oxidative metabolism due
to increased GABAergic tone (Hyder et al., 2006) could be
an indirect mechanism by which increased ammonia reduces
whole-brain oxidative metabolism of neurons in this condition
(Gjedde et al., 1978, 2010; Leke et al., 2011; Schousboe et al.,
2014).
In conclusion, the present study does not support the work-
ing hypothesis that the reduction in CMRO2 during HE in
patients with cirrhosis reflects reduced oxidative metabolism
by astrocytes. Hence, the reduced CMRO2 during HE is likely
to be related to metabolic effects of the condition of HE in
neurons.
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